How to buy Atreca stock | $9.02

Atreca, Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 134 staff and has a market cap (total outstanding shares value) of 0.00.

Atreca stock price (NASDAQ: BCEL)

Use our graph to track the performance of BCEL stocks over time.

Atreca shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$9.02
52-week range	$4.80 - $20.29
50-day moving average	$8.38
200-day moving average	$12.36
Wall St. target price	$29.89
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-18.88

Buy Atreca shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Atreca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Atreca, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atreca price performance over time

Historical closes compared with the close of $9.02 from 2021-05-28

1 week (2021-07-20)	N/A
1 month (2021-07-01)	4.28%
3 months (2021-04-30)	-24.46%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Atreca financials

Gross profit TTM	$0
Return on assets TTM	-26.59%
Return on equity TTM	-46.84%
Profit margin	0%
Book value	$6.00
Market capitalisation	$202.5 million

TTM: trailing 12 months

Shorting Atreca shares

There are currently 6.9 million Atreca shares held short by investors – that's known as Atreca's "short interest". This figure is 4.1% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Atreca shares can be evaluated.

Atreca's "short interest ratio" (SIR)

Atreca's "short interest ratio" (SIR) is the quantity of Atreca shares currently shorted divided by the average quantity of Atreca shares traded daily (recently around 1.4 million). Atreca's SIR currently stands at 4.85. In other words for every 100,000 Atreca shares traded daily on the market, roughly 4850 shares are currently held short.

However Atreca's short interest can also be evaluated against the total number of Atreca shares, or, against the total number of tradable Atreca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atreca's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Atreca shares in existence, roughly 190 shares are currently held short) or 0.3728% of the tradable shares (for every 100,000 tradable Atreca shares, roughly 373 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Atreca.

Find out more about how you can short Atreca stock.

Atreca share dividends

We're not expecting Atreca to pay a dividend over the next 12 months.

Atreca share price volatility

Over the last 12 months, Atreca's shares have ranged in value from as little as $4.8 up to $20.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atreca's is 0.0536. This would suggest that Atreca's shares are less volatile than average (for this exchange).

Atreca overview

Atreca, Inc. , a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc.

Frequently asked questions

What percentage of Atreca is owned by insiders or institutions?
Currently 3.287% of Atreca shares are held by insiders and 94.512% by institutions. How many people work for Atreca?
Latest data suggests 134 work at Atreca. When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December. Where is Atreca based?
Atreca's address is: 450 East Jamie Court, South San Francisco, CA, United States, 94080 What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094 What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109